ART (Advanced Research Technologies) gains imaging biomarker from Alerion
This article was originally published in Clinica
Executive Summary
Canadian imaging company ART (Advanced Research Technologies) is now able to offer biomarkers and contrast media to users of its preclinical and clinical imaging devices, following the acquisition of US imaging agents developer Alerion Biomedical. The move not only provides ART with a new stream of recurring revenues, it also gives the firm access to the $5bn global biomarker and radiopharmaceutical market.